Skip to main content

Table 2 Baseline characteristics of studies in carbapenem-resistant P. aeruginosa

From: Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Author Year Design Country Case/Exposure Control/Comparator Total N Age cases (Yr) Age control (Yr) Male cases (%) Male control (%)
D’Agata (a) [17] 2006 CC, matched USA, Italy CRPA Non-P. aeruginosa 82 61 60 73 44
DalBen [42] 2013 P, cohort Brazil MRAC and CRPA Non-MRAC and non-CRPA 325 44 41 59 41
Djordjevic [43] 2013 P, cohort Serbia CRPA CSPA 261 59.2 61.4 80.8 64.9
Eagye (a) [44] 2009 CC, control USA MRPA MSPA 183 66.4 66.1 58.6 59.2
Eagye (b) [44] 2009 CC, control USA MRPA Non-P. aeruginosa 182 66.4 57.4 58.6 50.9
Fortaleza (a) [45] 2006 CC, matched Brazil IRPA Control (NR) 324 median 45 median 44 68.5 60.2
Furtado [46] 2009 CC, matched Brazil IRPA Without IRPA 245 50 54 68.3 59.3
Furtado [47] 2010 CC, matched Brazil IRPA Non-IRPA 295 54 54 70.7 56.5
Harris [50] 2002 CC, matched USA IRPA Without IRPA 866 55.7 49.4 39.1 39.1
Harris [51] 2011 P, cohort USA IRPA Non-IRPA 3146 56.7 55.7 61.9 56.7
Kohlenberg [54] 2010 CC, unmatched Germany CRPA CSPA 33 median 60 median 44.4 53.3 72.2
Lautenbach [55] 2010 CC, unmatched USA IRPA ISPA 2542 61 (total) 61 (total) 63.3 56.1
Lee [56] 2015 CC, matched Taiwan CRPA All susceptible P. aeruginosa 75 61.6 62 48 48
Lin [57] 2016 CC, unmatched Taiwan CRPA CSPA 164 66.6 63.5 72 67.1
Luyt [58] 2014 P, cohort France CRPA CSPA 169 57.6 57.9 65 66
Onguru [59] 2008 P, cohort Turkey IRPA ISPA 170 45.9 49.7 72 66.3
Pena [60] 2007 P, cohort Spain CRPA CSPA 254 59.8 57.1 60 65
Pereira [61] 2008 CC, unmatched Brazil IRPA ISPA 59 51.8 50.7 70 55
Tam [62] 2007 CC, unmatched USA CRPA Pan-susceptible P. aeruginosa 51 50 64 33 73
Tuon [40] 2012 CC, unmatched Brazil CRPA CSPA 77 46.4 49 75.9 70.8
Zavascki (a) [64] 2005 CC, unmatched Brazil IRPA Non P. aeruginosa 186 58 51 60 53
Zavascki (b) [64] 2005 CC, unmatched Brazil IRPA ISPA 158 58 51 60 66
Zhang [65] 2009 CC, unmatched China CRPA CSPA 34 61 50 NR NR
  1. CC case-control, CRPA carbapenem-resistantP. aeruginosa, CSPA carbapenem-susceptible P.aeruginosa, ICU Intensive Care Unit, IRPA imipenem-resistant P. aeruginosa, ISPA imipenem-susceptible P.aeruginosa, MRAC meropenem-resistant Acinetobacter baumannii, MRPA meropenem-resistant P. aeruginosa, MSPA meropenem-susceptible P. aeruginosa, NR not reported,k P parallel, SICU Surgical Intensive Care Unit, YR year
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us